Ocugen, Inc. · NASDAQ:OCGN
Ocugen — Investor Day (November 2022)
9 slides from Ocugen's investor day presentation, Nov 1, 2022
Slide 1: Long-Term Outlook
Long-Term Outlook Shankar Musunuri, PhD, MBA Chairman of the Board, CEO & Co-founder R&D Day November 1, 2022
Slide 2: Forward Looking Statements
Forward Looking Statements 2 This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are based on the beliefs and assumptions of Ocugen, Inc. and on information currently available to management. All statements contained
Slide 3: We're Here to Make an Impact Through Courageous Innovation
We’re Here to Make an Impact Through Courageous Innovation 3 Mission: Developing cutting-edge innovations for people facing serious disease and conditions with a commitment to ensuring global market access Pioneering modifier gene therapy for inherited retinal diseases, as well as larger blindness d
Slide 4: Pipeline Overview
4 Pipeline Overview Asset/Program Indication Current Status Vaccines COVAXIN™ (BBV152) SARS-CoV-2 virus COVID-19 • EUA for adults in Mexico; EUA for 5 to 18-year-olds submitted • Recruitment completed for U.S. Phase 2/3 Immuno-bridging and broadening clinical trial OCU500 Mucosal vaccine COVID-19 •
Slide 5: Corporate Executive Summary
Corporate Executive Summary Ocugen has an exciting and unique portfolio spanning ocular gene therapies, a novel biologic, an orthopedic regenerative cell therapy, and COVID-19 vaccines. We believe the modifier gene therapy platform assets (OCU400 and OCU410) are the most significant drivers of value
Slide 6: Modifier Gene Therapy Platform—Compelling Value Proposition with Potential to Meaningfully Disrupt the Market
Modifier Gene Therapy Platform—Compelling Value Proposition with Potential to Meaningfully Disrupt the Market Traditional single-gene augmentation transfers a functional version of a non-functional gene into target cells – This approach is limited by its ability to address one gene mutation at a tim
Slide 7: Potential Market Opportunity for Ocugen Gene Therapies—Revenue Potential of up to ~$40B in 2032
Potential Market Opportunity for Ocugen Gene Therapies— Revenue Potential of up to ~$40B in 2032 # Doses (in Thousands)* OCU400 6.0 18.6 19.8 25.5 29.4 34.1 39.5 OCU410 - 11.7 24.1 32.1 50.2 71.5 79.3 Forecasted Net-Revenue (OCU400, OCU410) Key Assumptions – 90% Ability-To-Pay (adjusting for afforda
Slide 8: Key Potential Milestones for Portfolio Assets
Key Potential Milestones for Portfolio Assets C UR RE N T PO RT FO LI O M IIL ES TO N ES CA PI TA L AV AI LA BL E 2022 2023 2024 2025 2026 2027 OCU500 (mucosal) Ph I/II (Potential EUA Path) COVAXIN Ph 3 Safety US BLA Filing US BLA FilingNeoCart® Phase III BLA Filing BLA FilingOCU400 Ph I/II Global P
Slide 9: Ocugen Vision
9 Ocugen™ Vision Fully integrated, patient-centric biotech company focused on vaccines in support of public health and gene and cell therapies targeting unmet medical needs through Courageous Innovation